Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR ANBENITAMAB (KN026) AND DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT ACCEPTED BY

VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION FOR ANBENITAMAB (KN026) AND DOCETAXEL FOR INJECTION (ALBUMIN-BOUND) (HB1801) FOR NEOADJUVANT TREATMENT ACCEPTED BY

August 04, 2026

a260804_00.png

Previous: VOLUNTARY ANNOUNCEMENT - SYS6037 INJECTION (MPOX MRNA VACCINE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

Next: VOLUNTARY ANNOUNCEMENT - PHASE IB/II CLINICAL TRIAL OF SYS 6090 INJECTION FOR THE TREATMENT OF COLORECTAL CANCER OFFICIALLY INITIATED AT THE FIRST CENTRE IN CHI

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号

Wechat